A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
Trial ID or NCT#
NCT00250432,
Status
NOT RECRUITING
Purpose
Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast infections)
Official Title
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Clinical and Laboratory evidence of blood stream &/or systemic candida infections
Exclusion Criteria:
- - Possible candida contamination - Candida colonization (non invasive infection), urine, cardiac, bone or brain and prosthetic device infections - Acute or moderately severe liver disease - Abnormal liver function tests - Abnormal blood clotting for patients on blood thinners
Investigator(s)
Wes (Janice) Brown
Contact us to find out if this trial is right for you.
Contact
Joanna Schaenman
View on ClinicalTrials.gov
